Sugi Predict

Sugi Predict / Compounds / SCHEMBL1269684

SCHEMBL1269684

SCHEMBL1269684

COC(=O)C1CC(=O)N(Cc2ccc(OC)cc2)C1

nearest known ligand 0.76

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.67
▸ CYP2C19 P33261 2/20 0.67
▸ KMT2A Q03164 1/20 0.65
▸ ALDH1A1 P00352 4/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.62
▸ MAPK1 P28482 2/20 0.61
▸ ALOX15 P16050 1/20 0.61
▸ LMNA P02545 1/20 0.60
▸ CYP2D6 P10635 1/20 0.60
▸ CYP2C9 P11712 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.58
▸ HTT P42858 1/20 0.53
▸ MMP1 P03956 1/20 0.53
▸ MMP13 P45452 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18820798 0.89 ALDH1A1 (0.72) CYP3A4CYP2C19KMT2AALDH1A1L3MBTL1
SCHEMBL12415404 0.88 SMN1; SMN2 (0.73) KMT2AALDH1A1L3MBTL1SMN1; SMN2LMNA
SCHEMBL6272090 0.88 KMT2A (0.64) CYP3A4CYP2C19KMT2AALDH1A1SMN1; SMN2
SCHEMBL1710890 0.88 ALDH1A1 (0.65) CYP3A4CYP2C19KMT2AALDH1A1L3MBTL1
SCHEMBL4095420 0.88 SMN1; SMN2 (0.73) CYP3A4CYP2C19KMT2AALDH1A1L3MBTL1
SCHEMBL3488893 0.87 KMT2A (0.56) CYP3A4CYP2C19KMT2AALDH1A1L3MBTL1
SCHEMBL15415933 0.87 ALDH1A1 (0.64) CYP3A4CYP2C19KMT2AALDH1A1L3MBTL1
SCHEMBL5970008 0.86 ALDH1A1 (0.62) KMT2AALDH1A1L3MBTL1SMN1; SMN2MAPK1
SCHEMBL2584810 0.86 ALDH1A1 (0.62) KMT2AALDH1A1L3MBTL1SMN1; SMN2MAPK1
SCHEMBL2191833 0.83 ALDH1A1 (0.59) CYP3A4CYP2C19KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116921-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2024-04-11 — — US disclosed
EP-4267137-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 Enliven Inc. (US) 2023-11-01 — — EP disclosed
CN-115594680-A TEAD inhibitor 武汉人福创新药物研发中心有限公司（CN） 2023-01-13 — — CN disclosed
WO-2023280254-A1 TEAD INHIBITOR 武汉人福创新药物研发中心有限公司 2023-01-12 — — WO disclosed
WO-2023280254-A1 TEAD INHIBITOR 武汉人福创新药物研发中心有限公司 2023-01-12 — — WO disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 — — WO disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 — — WO disclosed
EP-3052494-B1 AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS HOFFMANN LA ROCHE (CH) 2018-12-26 — — EP disclosed
US-9951064-B2 Azaindazole compounds as inhibitors of T790M containing EGFR mutants GENENTECH, INC. (US) 2018-04-24 — — US disclosed
US-9951064-B2 Azaindazole compounds as inhibitors of T790M containing EGFR mutants GENENTECH, INC. (US) 2018-04-24 — — US disclosed
US-6642398-B2 Improving drug qualities such as bioavailability and stability WARNER-LAMBERT COMPANY 2003-11-04 — — US disclosed
US-20030181523-A1 Mono-and disubstituted 3-propyl gamma-aminobutyric acids BELLIOTTI THOMAS RICHARD (US) 2003-09-25 — — US disclosed
US-20030176504-A1 Method of treating tinnitus DOOLEY DAVID JAMES (US) 2003-09-18 — — US disclosed
US-6620829-B2 Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt WARNER-LAMBERT COMPANY 2003-09-16 — — US disclosed
WO-2003063845-A1 ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS WARNER-LAMBERT COMPANY LLC (US) 2003-08-07 — — WO disclosed
US-20020072533-A1 Method of treating cartilage damage SCHRIER DENIS (US) 2002-06-13 — — US disclosed
EP-1199072-A2 Method of treating cartilage damage WARNER-LAMBERT COMPANY (US) 2002-04-24 — — EP disclosed
EP-1192125-A2 MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS WARNER-LAMBERT COMPANY (US) 2002-04-03 — — EP disclosed
WO-2000076958-A2 MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS WARNER-LAMBERT COMPANY (US) 2000-12-21 — — WO disclosed
US-5541343-A ANTIAGGLOMERANTS FOR CELLS OR ANTICOAGULANTS KARL THOMAE GMBH (DE) 1996-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176504-A1 Method of treating tinnitus ADRA2A, ADRA1A, ADRA1D CYP3A4 1923/4885CYP2C19 1427/4885KMT2A 823/4885
US-20020072533-A1 Method of treating cartilage damage COL2A1, COL1A1, GABRB1 CYP3A4 2967/4885CYP2C19 2770/4885KMT2A 3421/4885
US-20240116921-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ERBB2, FGFR2, ERBB3 CYP3A4 531/4885CYP2C19 122/4885KMT2A 2747/4885
US-20030181523-A1 Mono-and disubstituted 3-propyl gamma-aminobutyric acids GABRB1, GABRA1, GABRB3 CYP3A4 561/4885CYP2C19 214/4885KMT2A 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.